Cada año, miles de personas caen de manera inesperada a causa de un colapso súbito. En ese preciso momento, todo parece detenerse y la línea entre vida y muerte se convierte en una cuestión de segundos y en una carrera en la que cualquiera puede ser el héroe. Saber …
A recruiter and career coach discuss when and why some biotech and pharma professionals put a premium on health insurance benefits.
Over 1/3 stay in biopharma jobs for health insurance, poll finds Read More »
The value-based primary care provider submitted false diagnosis codes to the CMS for three years, inflating its reimbursement by millions of dollars, according to the DOJ.
Complete Health to pay $14M to settle Medicare Advantage fraud allegations Read More »
Seven months after launching with $16 million in seed financing, Jennifer Doudna’s Aurora Therapeutics is pivoting away from its lead indication, phenylketonuria, owing to growing competition in the field.
Bespoke gene-editing outfit abandons lead program, cuts ‘several’ employees Read More »
Reuters has deflated rumors that AstraZeneca and Bristol Myers Squibb are discussing a possible merger, letting the air out of industry-wide speculation over what could have been the largest deal in pharma history.
No deal between AstraZeneca and BMS, senior source insists: Reuters Read More »
Nearly 380,000 patients could go out of network with the health system if the commercial, Medicare and Medicaid contracts lapse.
Sentara moves to end Anthem contracts in Virginia Read More »
Amgen has discontinued Phase 1 obesity candidate AMG 513, leaving MariTide as its sole weight loss asset. Meanwhile, executives said the company’s late-stage pipeline is largely full and future business development will focus on earlier-stage opportunities.
Amgen’s MariTide stands alone after obesity cull while analysts seek more M&A Read More »
Eli Lilly’s shares rose nearly 5% to $1,170 apiece in premarket trading as the company reported $23 billion in revenue for the second quarter. The company’s market cap is $1.02 trillion as of the end of July.
Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 Read More »
HIV remained Gilead’s strongest franchise in the second quarter, but the pharma is building out its pipeline beyond virology, particularly focusing on inflammation and oncology.
Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts Read More »
The FDA has been trying to mend fences with rare disease drug developers and patient groups since the departure of former Commissioner Marty Makary three months ago. But advisory committee meetings last week for Replimune and Capricor Therapeutics only created more confusion and frustration.
Chaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad Read More »
